 Recent multi-center trials have shown tenofovir disoprovil fumarate TDF demonstrating potent antiviral efficacy in both nucleoside-naive and -experienced chronic hepatitis B CHB patients. At present, there has been no identifiable amino acid substitutions associated with resistance to TDF. 